Giovanni Caforio, Bristol Myers Squibb CEO
July 27, 2022 01:53 PM EDTUpdated July 28, 06:57 AM
Deals
Pharma

More deals ahead for Bris­tol My­ers? CEO Gio­van­ni Caforio touts 'size ag­nos­tic' BD strat­e­gy

Nicole DeFeudis

Editor

De­spite gener­ics eat­ing away at one of Bris­tol My­ers Squibb’s high­est sell­ers last year, Revlim­id, CEO Gio­van­ni Caforio main­tained on Wednes­day’s Q2 call that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times